BMO Capital analyst George Farmer initiated Eidos Therapeutics with an Outperform rating and $28 price target. The analyst receommends buying shares as he sees huge potential for AG10 for the treatment of transthyretin amyloidosis, and estimates peak sales of $3B by 2031.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.